{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nausea-vomiting-in-pregnancy/prescribing-information/prochlorperazine/","result":{"pageContext":{"chapter":{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine","depth":2,"htmlHeader":"<!-- begin field 42fe7627-8406-4ee7-ae81-6691bcadecd6 --><h2>Prochlorperazine</h2><!-- end field 42fe7627-8406-4ee7-ae81-6691bcadecd6 -->","summary":"","htmlStringContent":"<!-- begin item 5ca86f8e-8115-433c-8d07-505497165bed --><!-- end item 5ca86f8e-8115-433c-8d07-505497165bed -->","topic":{"id":"5d1ac05e-2e14-5b50-9a55-84ebd62fb88a","topicId":"866e168a-d1cc-4f14-ae38-2264dad4909d","topicName":"Nausea/vomiting in pregnancy","slug":"nausea-vomiting-in-pregnancy","lastRevised":"Last revised in November 2020","chapters":[{"id":"2ed30ea1-6303-508e-bc93-066f8ffbbba6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81163ec6-a53e-53b1-9990-910cceb0be62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes"},{"id":"845aae6a-8e35-57f1-b583-4763434044df","slug":"update","fullItemName":"Update"}]},{"id":"21afb631-a6c0-5829-b00a-3b33bef92b50","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"61081bb4-4afa-59ad-8401-21a133c7ac1e","slug":"goals","fullItemName":"Goals"},{"id":"5e20514d-0378-56ab-a9c4-6adb3b054200","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5af11c90-393d-59dd-9a48-c750bc1a8a14","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"51bcef1b-8089-52c9-92cc-1fa55932d88b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef8fc985-dc5b-58a5-a2ff-ca6e9d55cfb8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f559ccd0-5b31-5044-9e75-d75ab6224e12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2664bbce-4231-58ba-94b3-9154bbe463ce","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"474f1c82-889d-5487-9620-c2c4c6869f1b","slug":"definition","fullItemName":"Definition"},{"id":"8eb8a14e-f0bc-5bde-941f-077c2ebf80e8","slug":"causes","fullItemName":"Causes"},{"id":"6086e58d-ce8f-56ba-8bc9-6769de656e20","slug":"associated-factors","fullItemName":"Associated factors"},{"id":"843ada21-2019-53fe-96b9-02ac02e7d0f2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"87b6f2c0-0cd6-59f3-9359-e145dc966385","slug":"complications","fullItemName":"Complications"}]},{"id":"d56e419a-1cce-586b-b99b-a5b8a8990006","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f17249a-f4a8-55a7-aac0-221f3958f18f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b917da16-f352-5806-8109-438dbc9bbf0b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"92cdc482-cd10-5234-96f9-a47cf0d7a2d1","fullItemName":"Management","slug":"management","subChapters":[{"id":"110c4bdc-fe27-5536-9a99-bfbcf04edc46","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide"},{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron"},{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine"}]},{"id":"85b35812-d5b1-58c1-83b2-54c180386588","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1a1884de-e81c-54af-b11f-6b0868c50cc8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8a6cb0f6-92e2-57f4-9a1e-bf9e54371e08","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dc13c44-10ce-581a-a0a4-039b81c0c21e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cb1eb43f-2d9f-59be-8318-3bd84b8d0c3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b024ff4-e12a-55bd-ae23-668d6ca9e645","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e5cef950-067b-517f-9adb-2be42bf3be6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dbe95893-89e8-5737-9b03-95b5280f9823","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fdadc067-77d8-5620-8859-26f73b76a1ca","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 9074db15-15ce-41a7-8e97-a77400a93990 --><h3>What dosage of prochlorperazine should I prescribe?</h3><!-- end field 9074db15-15ce-41a7-8e97-a77400a93990 -->","summary":"","htmlStringContent":"<!-- begin item a813357c-b550-4ffd-acff-a77400a9377a --><!-- begin field 1d9b0587-2e0e-46e9-a9b2-a77400a93990 --><ul><li>Prescribe prochlorperazine:<ul><li>Oral tablets 5–10 mg up to three times a day.</li><li>Buccal tablets 3–6 mg twice a day.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">UKMi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF for Children, 2017</a>]</p><!-- end field 1d9b0587-2e0e-46e9-a9b2-a77400a93990 --><!-- end item a813357c-b550-4ffd-acff-a77400a9377a -->","subChapters":[]},{"id":"f9a77f09-424e-573a-be4b-fff6be095829","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3ee1cd63-925f-4932-a327-a77400a9706e --><h3>What are the adverse effects of prochlorperazine?</h3><!-- end field 3ee1cd63-925f-4932-a327-a77400a9706e -->","summary":"","htmlStringContent":"<!-- begin item 85a1b3f0-91d5-4106-ab5e-a77400a96e31 --><!-- begin field aa45269c-a731-4277-b1a2-a77400a9706e --><ul><li><strong>Extrapyramidal symptoms</strong><ul><li>These depend on the dose and the susceptibility of the individual person:<ul><li>Parkinsonian symptoms (including tremor) may occur more commonly in adults or the elderly and may appear gradually.</li><li>Dystonia (abnormal face and body movements) and dyskinesia are more common in young people and can occur after only a few doses.</li><li>Akathisia (restlessness) characteristically occurs after large initial doses.</li><li>Tardive dyskinesia (rhythmic, involuntary movements of tongue, face, and jaw) usually develops on long-term treatment or with high doses, but it may develop on short-term treatment with low doses. Withdrawal of prochlorperazine may cause short-lived tardive dyskinesia. Tardive dyskinesia is of particular concern because it may be irreversible even if therapy is withdrawn, and treatment for this is not usually effective.</li></ul></li></ul></li><li><strong>Endocrine disorders</strong><ul><li>Hyperprolactinaemia which may result in galactorrhoea, gynaecomastia, and amenorrhoea has been reported following treatment with prochlorperazine.</li></ul></li><li><strong>Cardiac disorders</strong><ul><li>Cardiac arrhythmias, including atrial arrhythmia, atrioventricular block, ventricular fibrillation, and ventricular tachycardia (rare), have been reported. QT prolongation, sudden death, cardiac arrest, and Torsades de points have also occurred following treatment with prochlorperazine.</li><li>Pre-existing cardiac disease, family history of QT prolongation, increasing age, hypokalaemia, and concurrent use of other drugs known to prolong the QT interval may predispose people to these effects.</li></ul></li><li><strong>Blood and lymphatic system disorders</strong><ul><li>Mild leucopenia occurs in up to 30% of people on high doses of prochlorperazine for a prolonged period of time.</li><li>Agranulocytosis may occur rarely, but it is not related to the dose. If unexplained infections or fever occur, immediate haematological investigation is required.</li><li>Cases of venous thromboembolism have also been reported with prochlorperazine.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Nervous system disorders — drowsiness, apathy, agitation, excitement, insomnia, convulsions, dizziness, headache, and confusion.</li><li>Antimuscarinic effects — dry mouth, constipation, difficulty with micturition, blurred vision, and precipitation of angle-closure glaucoma (very rare).</li><li>Skin and tissue disorders — photosensitization, contact sensitization, rashes, and purplish pigmentation of the skin.</li><li>Hepatobiliary disorders — jaundice (including cholestatic).</li><li>Eye disorders — corneal and lens opacities and purplish pigmentation of the cornea, conjunctiva, and retina.</li><li>Others — nasal congestion.</li></ul></li><li>Neonates, if exposed to prochlorperazine in the third trimester of pregnancy, may experience extrapyramidal and/or withdrawal symptoms. Reported effects include agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field aa45269c-a731-4277-b1a2-a77400a9706e --><!-- end item 85a1b3f0-91d5-4106-ab5e-a77400a96e31 -->","subChapters":[]},{"id":"90492d26-d847-5218-ace6-02365889b520","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field dcaa371b-9312-4519-aa8b-a77400a95417 --><h3>What are the contraindications and cautions when prescribing prochlorperazine?</h3><!-- end field dcaa371b-9312-4519-aa8b-a77400a95417 -->","summary":"","htmlStringContent":"<!-- begin item ddb25b2f-144f-418a-8e6b-a77400a951f1 --><!-- begin field 9ce06d10-9589-4c55-9d3d-a77400a95417 --><ul><li><strong>Do not prescribe prochlorperazine</strong> <strong>to: </strong> <ul><li>People with:<ul><li>Phaeochromocytoma.</li><li>Liver or renal dysfunction.</li><li>History of jaundice.</li><li>Parkinson's disease.</li><li>Hypothyroidism.</li><li>Heart failure.</li><li>Myasthenia gravis.</li><li>Prostate hypertrophy.</li><li>A history of angle closure glaucoma.</li><li>Agranulocytosis.</li></ul></li></ul></li><li><strong>Prescribe prochlorperazine with caution to:</strong><ul><li>People with epilepsy or a history of seizures — close monitoring is required in this group of people as prochlorperazine may lower the seizure threshold.</li><li>Elderly people — use with caution, especially during very hot or cold weather due to the risk of hyper- or hypothermia.</li><li>People with cardiovascular disease or family history of QT prolongation — cases of QT interval prolongation have been very rarely reported with prochlorperazine. An alternative anti-emetic should be considered for people with with predisposing factors for ventricular arrhythmias, or they should be carefully monitored (check electrolytes and bone chemistry), particularly during the initial phase of treatment.<ul><li>Cardiac disease; metabolic abnormalities such as hypokalaemia, hypocalcaemia, or hypomagnesaemia; starvation; alcohol misuse; and concurrent treatment with other drugs known to prolong the QT interval may predispose people to ventricular arrhythmias.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017b</a>]</p><!-- end field 9ce06d10-9589-4c55-9d3d-a77400a95417 --><!-- end item ddb25b2f-144f-418a-8e6b-a77400a951f1 -->","subChapters":[]},{"id":"212e068d-cfc3-58f0-a316-56ab189d356a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 276ad62b-3286-4bef-b35b-a77400a98ab0 --><h3>What drug interactions occur with prochlorperazine?</h3><!-- end field 276ad62b-3286-4bef-b35b-a77400a98ab0 -->","summary":"","htmlStringContent":"<!-- begin item b1dbb234-90a2-464b-95a7-a77400a98859 --><!-- begin field d5222af3-fca1-427f-94b1-a77400a98ab0 --><ul><li><strong>Alcohol </strong>— advise the person to avoid taking alcohol whilst taking prochlorperazine.<ul><li>The sedative effects of alcohol on driving and operating heavy machinery may be enhanced by prochlorperazine.</li></ul></li><li><strong>Antimuscarinic drugs </strong>— there is a risk of increased antimuscarinic adverse effects when prochlorperazine is given with other antimuscarinic drugs, especially in elderly people.<ul><li>In addition, plasma concentrations of prochlorperazine are reduced by antimuscarinics.</li></ul></li><li><strong>Antiepileptic drugs </strong>— monitor phenytoin plasma concentrations.<ul><li>Plasma concentrations of phenytoin may be raised or lowered by prochlorperazine.</li></ul></li><li><strong>Antihypertensive drugs </strong>— monitor blood pressure carefully. Warn the person about the possibility of postural hypotension, and counsel them on how to manage it (by lying down, raising the legs, and getting up slowly when they feel better).<ul><li>The hypotensive effect of most antihypertensive drugs (particularly alpha-adrenoceptor blockers and calcium channel blockers) may be increased by prochlorperazine.</li></ul></li><li><strong>Cimetidine </strong>— plasma concentrations of prochlorperazine may be increased or decreased by cimetidine. Excessive sedation may occur and it may be necessary to reduce the dose of prochlorperazine.</li><li><strong>Central nervous system (CNS) depressants </strong>— be aware of possible adverse effects with prochlorperazine.<ul><li>The CNS depressant actions of prochlorperazine may be increased by barbiturates, opioid analgesics, anxiolytics, and hypnotics.</li><li>Concurrent use has resulted in excessive sedation, severe hypotension, respiratory depression, and neuroleptic malignant syndrome (rare).</li></ul></li><li><strong>Drugs which prolong the QT interval </strong>— there is an increased risk of ventricular arrhythmias when prochlorperazine is used concurrently with drugs that prolong the QT interval, for example anti-arrhythmics, sotalol, antidepressants (tricyclics, citalopram, and escitalopram), antihistamines (terfenadine), methadone, and risperidone.</li><li><strong>Lithium </strong>— monitor concurrent use closely.<ul><li>There is an increased risk of extrapyramidal adverse effects and possibly neurotoxicity when prochlorperazine is given with lithium. Dose adjustments may be needed to manage adverse effects of concurrent use with prochlorperazine.</li></ul></li><li><strong>Sulphonylureas </strong>— monitor blood sugar closely.<ul><li>The hypoglycaemic effect of sulphonylureas (such as gliclazide) may possibly be antagonized by prochlorperazine. The dose of the sulphonylurea may need to be increased.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field d5222af3-fca1-427f-94b1-a77400a98ab0 --><!-- end item b1dbb234-90a2-464b-95a7-a77400a98859 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}